Decision and Details
Research results and views regarding obesity and non-alcoholic fatty liver disease involving the PAI-1 inhibitors RS5614 and RS5441
Disclosed to enhance communication with investors and ensure fair disclosure. The company is focusing on the anti-obesity effects of PAI-1 inhibitors as one potential contributor to anti-aging and longevity effects.
| Item | Details |
|---|---|
| Matter Covered | Research results and views regarding obesity and non-alcoholic fatty liver disease involving the PAI-1 inhibitors RS5614 and RS5441 |
| Decision Date | 16 July 2026 (disclosure date) |
| Quantity / scale | Mouse body weight: 37.6±1.07 g in the control group and 33.8±0.97 g in the treated group. High-fat, high-glucose diet administration period: 8 weeks; body weight evaluated 35 days after administration |
| Reason | Disclosed to enhance communication with investors and ensure fair disclosure. The company is focusing on the anti-obesity effects of PAI-1 inhibitors as one potential contributor to anti-aging and longevity effects. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company disclosed the main questions received and its answers to enhance communication with investors and ensure fair disclosure. As obesity is a factor in the progression of age-related diseases and sarcopenia, the company is focusing on the anti-obesity effects of PAI-1 inhibitors as one potential contributor to anti-aging and longevity effects.